- Home
- M vs RYTM Comparison
M vs RYTM Comparison
Compare M & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | M | RYTM |
|---|---|---|
| Founded | 1830 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | M | RYTM |
|---|---|---|
| Price | $21.99 | $108.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $19.89 | ★ $128.54 |
| AVG Volume (30 Days) | ★ 6.1M | 816.4K |
| Earning Date | 03-05-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ 331.62 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $22,712,000,000.00 | $174,334,000.00 |
| Revenue This Year | N/A | $47.34 |
| Revenue Next Year | N/A | $55.95 |
| P/E Ratio | $12.81 | ★ N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $9.76 | $45.91 |
| 52 Week High | $24.41 | $122.20 |
Technical Indicators
Market Signals| Indicator | M | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 46.89 | 53.88 |
| Support Level | $21.17 | $96.20 |
| Resistance Level | $24.02 | $103.20 |
| Average True Range (ATR) | 0.72 | 4.59 |
| MACD | -0.15 | -0.44 |
| Stochastic Oscillator | 30.87 | 66.21 |
Price Performance
Historical ComparisonAbout M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's name, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.